Basics Halozyme Therapeutics, Inc. Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment. IPO Date: March 16, 2004 Sector: Healthcare Industry: Biotech Market Cap: $6.71B Activated in VL: True Average Daily Range Avg Daily Range: $0.37 | 2.17% Avg Daily Range (30 D): $1.38 | 2.38% Avg Daily Range (90 D): $1.03 | 1.76% Institutional Daily Volume Avg Daily Volume: .95M Avg Daily Volume (30 D): 2.31M Avg Daily Volume (90 D): 1.51M Trade Size Avg Trade Size (Sh.): 109 Avg Trade Size (Sh.) (30 D): 65 Avg Trade Size (Sh.) (90 D): 58 Institutional Trades Total Inst.Trades: 8,819 Avg Inst. Trade: $2.65M Avg Inst. Trade (30 D): $3.36M Avg Inst. Trade (90 D): $3.82M Avg Inst. Trade Volume: .08M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $5.03M Avg Closing Trade (30 D): $16.37M Avg Closing Trade (90 D): $16.13M Avg Closing Volume: 152.02K         News Apr 10, 2025 @ 9:47 PM argenx Announces FDA Approval of VYVGART Hytrulo P... Source: N/A Nov 11, 2024 @ 4:59 PM Needle Free Injectors Market Is Expected To Reach ... Source: Dimension Market Research Jun 27, 2024 @ 1:50 PM Why This 1 Momentum Stock Could Be a Great Additio... Source: Zacks Equity Research Jun 20, 2024 @ 1:45 PM Are You a Growth Investor? This 1 Stock Could Be t... Source: Zacks Equity Research Jun 17, 2024 @ 1:40 PM Here's Why Halozyme Therapeutics (HALO) is a Stron... Source: Zacks Equity Research Financials   TTM Q1 2025 Q4 2024 Basic EPS $3.85 $.96 $1.08 Diluted EPS $3.76 $.93 $1.06 Revenue $ 1.08B $ 264.86M $ 298.01M Gross Profit $ 904.82M $ 216.46M $ 255.95M Net Income / Loss $ 485.36M $ 118.1M $ 137.01M Operating Income / Loss $ 597.47M $ 141.54M $ 175.5M Cost of Revenue $ 179.49M $ 48.4M $ 42.06M Net Cash Flow $ 11.7M $ 60.48M $ -38.47M PE Ratio 14.63